FMTX

Forma Therapeutics Holdings, Inc.

A biopharmaceutical company born in 2007 out of MIT and Harvard's Broad Institute, Forma Therapeutics develops drugs for rare blood diseases. Its lead experimental medicine, etavopivat, is an oral pill designed to help red blood cells work properly for people with sickle cell disease and thalassemia. The name comes from the Latin word for "form" or "shape," reflecting its focus on designing molecules to fit biological structures. In 2022 it became part of Danish drugmaker Novo Nordisk.

No Schedule 13D or 13G filings recorded.